Boule Diagnostics ABOMXSTO: BOUL

BOUL: Sales declined, but margins and EBIT improved amid restructuring and strong OEM growth

· Issued by Boule Diagnostics AB

Q3 saw a 6.6% sales decline, but gross margin and EBIT improved due to cost savings and a favorable mix. Major one-time costs included a SEK 265 million impairment and SEK 27 million write-down, while OEM growth and restructuring initiatives support a positive outlook for 2025.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Boule Diagnostics AB on 6ix

In the deck

Earlier from Boule Diagnostics

Later from Boule Diagnostics

All Boule Diagnostics news releases